Top News
Next Story
NewsPoint

Pfizer Jab Likely To Cost Rs 750 In India, Close To Getting Indemnity From Govt: Reports

Send Push
HW News English
10th June, 2021 22:00 IST
On the issue of protection against legal liability, something that Pfizer actively asked for from the government, sources have told Reuters that India is close to granting it. 

US pharmaceutical giant Pfizer’s COVID-19 vaccine may be priced at Rs 730 (under $10) which could be the lowest price for the mRNA-based jab globally. News reports have also quoted government sources that said that the Union government might waive off the much-contested indemnity clause.

“It is a single-digit price per dose. This is a not-for-profit price for the government’s immunization program,” Business Standard citing sources as saying. The two-shot vaccine has been made by the American pharma giant and its German partner BioNTech.

imagePfizer’s COVID-19 vaccine may be priced at Rs 730 (under $10)

If the vaccine comes under $10 in the country, the price would be almost half that of in developed markets like the United States, United Kingdom, and European Union, the report said.

The Pfizer COVID vaccine is priced in the US for $19.5 (Rs 1,423) a dose. In the UK, it costs around $21 (Rs 1,532). In the EU, earlier the price was around $18.9 a dose but price negotiations are underway for a higher price of $23.2 (Rs 1,693) a dose, as per the report.

“Currently, as our discussions with the government of India are ongoing and confidential, we cannot provide further details,” the spokesperson said.

Also Read: “MVA Govt Will Complete Full Term”: NCP Supremo Sharad Pawar

The Russian COVID-19 vaccine Sputnik V is priced in India at Rs 995 a dose (inclusive of all taxes) in the private market. The price for a dose of Covaxin, India’s first indigenously developed COVID-19 vaccine, is Rs 1,200 and of Oxford-AstraZeneca’s Covishield Rs 600 for private hospitals. For the Centre, the price Rs 150 a dose at present.

On the issue of protection against legal liability, something that Pfizer actively asked for from the government, sources have told Reuters that India is close to granting it.

“Indemnity will be granted,” said one of the sources. “If one company gets it then all of them get it.”

 

Explore more on Newspoint
Loving Newspoint? Download the app now